Drug intelligence / Profile preview

umbilical cord-derived mesenchymal stromal cell secretome

Development stage
Phase 2
Lead developer
Universitas Sriwijaya
Modality
Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intramuscular
01

Overview

Umbilical cord-derived mesenchymal stromal cell (UC-MSC) secretome is a cell-free therapeutic product consisting of the complete set of bioactive molecules secreted by UC-MSCs into their extracellular environment. This complex mixture includes cytokines, chemokines, growth factors, and extracellular vesicles (such as exosomes) that mediate the immunomodulatory, anti-inflammatory, and regenerative properties associated with MSC therapy. By utilizing the secretome rather than the cells themselves, this approach aims to provide the therapeutic benefits of MSCs while avoiding potential risks related to cell transplantation, such as immunogenicity or unwanted differentiation. In clinical development, particularly by Universitas Sriwijaya, it is being evaluated as an intramuscular adjunct therapy for moderate rheumatoid arthritis to reduce synovial inflammation and improve clinical outcomes in patients who are inadequately controlled by conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Other names
UC-MSC secretomeumbilical cord mesenchymal stem cell secretomeUC-MSC-CMumbilical cord-derived mesenchymal stem cell secretome
02

Targets

IL10 (Interleukin-10)IL-6 (Interleukin 6)TGFB1 (Transforming growth factor Beta-1 proprotein)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on umbilical cord-derived mesenchymal stromal cell secretome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on umbilical cord-derived mesenchymal stromal cell secretome.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call